Mayo Clinic researchers, along with national and global collaborators, have developed a potential test for Machado-Joseph disease, or spinocerebellar ataxia type 3 (SCA3)—a disease that has no cure.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 14, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with ...
Bioblast Pharma Ltd.ORPN announced positive results from a phase IIa study on its lead candidate, trehalose, for the treatment of patients with spinocerebellar ataxia type 3 (SCA3). A look at Bioblast ...
WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD) announced it has been awarded a $5.69 million grant from the California Institute for Regenerative Medicine (CIRM) to advance the ...
Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph Disease (MJD), describes the most common form of dominantly inherited ataxia in many populations worldwide, including Hong Kong and ...
A European research consortium (ESMI) led by Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) will be investigating the neurodegenerative disease “Spinocerebellar Ataxia Type 3” (SCA3) in ...
Niigata, Japan – Using machine learning, the Department of Neurology at Niigata University has developed a model to predict the asymptomatic probability at each age from the current age and number of ...
This pilot study was initiated to show the existence of founder effects in the Dutch autosomal dominant cerebellar ataxia (ADCA) population. The ADCAs comprise a clinically heterogeneous group of ...
Spinocerebellar ataxia type 3 (SCA3) is the most common autosomal dominant hereditary ataxia worldwide, with no cure available. Intranuclear aggregation of the mutant expanded ATXN3 protein is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results